肺動脈塞栓症(Pulmonary Embolism):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Pulmonary Embolism - Pipeline Review, H2 2014
◆商品コード:GMDHC5725IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における肺動脈塞栓症(Pulmonary Embolism)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・肺動脈塞栓症(Pulmonary Embolism)の概要
・肺動脈塞栓症(Pulmonary Embolism)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・肺動脈塞栓症(Pulmonary Embolism)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・肺動脈塞栓症(Pulmonary Embolism)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・肺動脈塞栓症(Pulmonary Embolism)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Pulmonary Embolism – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Pulmonary Embolism – Pipeline Review, H2 2014’, provides an overview of the Pulmonary Embolism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pulmonary Embolism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pulmonary Embolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Embolism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Embolism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Embolism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pulmonary Embolism Overview 6
Therapeutics Development 7
Pipeline Products for Pulmonary Embolism – Overview 7
Pipeline Products for Pulmonary Embolism – Comparative Analysis 8
Pulmonary Embolism – Therapeutics under Development by Companies 9
Pulmonary Embolism – Therapeutics under Investigation by Universities/Institutes 10
Pulmonary Embolism – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Pulmonary Embolism – Products under Development by Companies 14
Pulmonary Embolism – Products under Investigation by Universities/Institutes 15
Pulmonary Embolism – Companies Involved in Therapeutics Development 16
Bayer AG 16
Bristol-Myers Squibb Company 17
Daiichi Sankyo Company, Limited 18
F. Hoffmann-La Roche Ltd. 19
Pulmonary Embolism – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 27
apixaban – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
edoxaban tosylate – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
rivaroxaban – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule for Pulmonary Embolism and Hematological Disorders – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SMTP-7 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TRX-1 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Pulmonary Embolism – Recent Pipeline Updates 38
Pulmonary Embolism – Dormant Projects 58
Pulmonary Embolism – Discontinued Products 59
Pulmonary Embolism – Product Development Milestones 60
Featured News & Press Releases 60
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 60
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 61
Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014 62
Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 63
Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 65
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 65
Feb 17, 2014: Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention 66
Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE 67
Dec 09, 2013: Phase 3 Data Show Daiichi Sankyo’s Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer 68
Dec 03, 2013: New Data to be Presented on Bayer’s Xarelto Single-Drug Solution for the Treatment and Prevention of Recurrent Pulmonary Embolism and Deep Vein Thrombosis 70
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

[List of Tables]
Number of Products under Development for Pulmonary Embolism, H2 2014 7
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Pulmonary Embolism - Pipeline by Bayer AG, H2 2014 16
Pulmonary Embolism - Pipeline by Bristol-Myers Squibb Company, H2 2014 17
Pulmonary Embolism - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 18
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 26
Pulmonary Embolism Therapeutics - Recent Pipeline Updates, H2 2014 38
Pulmonary Embolism - Dormant Projects, H2 2014 58
Pulmonary Embolism - Discontinued Products, H2 2014 59

[List of Figures]
Number of Products under Development for Pulmonary Embolism, H2 2014 7
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Early Stage Products, H2 2014 13
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Top 10 Targets, H2 2014 21
Number of Products by Stage and Top 10 Targets, H2 2014 22
Number of Products by Top 10 Mechanism of Actions, H2 2014 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 25
Number of Products by Stage and Top 10 Molecule Types, H2 2014 26

【掲載企業】

Bayer AG
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
F. Hoffmann-La Roche Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[肺動脈塞栓症(Pulmonary Embolism):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆